Infection-Mimicking Materials to Program Dendritic Cells In Situ

Cancer vaccines typically depend on cumbersome and expensive manipulation of cells in the laboratory, and subsequent cell transplantation leads to poor lymph node homing and limited efficacy. We propose that materials mimicking key aspects of bacterial infection may instead be used to directly control immune cell trafficking and activation in the body. It is demonstrated that polymers can be designed to first release a cytokine to recruit and house host dendritic cells (DCs), and subsequently present cancer antigens and danger signals to activate the resident DCs and dramatically enhance their homing to lymph nodes. Specific and protective anti-tumor immunity was generated with these materials, as 90% survival was achieved in animals that otherwise die from cancer within 25 days. These materials show promise as cancer vaccines, and more broadly suggest that polymers may be designed to program and control the trafficking of a variety of cell types in the body.

[1]  E. Gilboa DC-based cancer vaccines. , 2007, The Journal of clinical investigation.

[2]  Linda G Griffith,et al.  Emerging Design Principles in Biomaterials and Scaffolds for Tissue Engineering , 2002, Annals of the New York Academy of Sciences.

[3]  Ira Mellman,et al.  Dendritic Cells Specialized and Regulated Antigen Processing Machines , 2001, Cell.

[4]  A. Krieg Development of TLR9 agonists for cancer therapy. , 2007, The Journal of clinical investigation.

[5]  D J Mooney,et al.  Bioabsorbable polymer scaffolds for tissue engineering capable of sustained growth factor delivery. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[6]  T. Brocker,et al.  Endogenous Dendritic Cells Are Required for Amplification of T Cell Responses Induced by Dendritic Cell Vaccines In Vivo 1 , 2003, The Journal of Immunology.

[7]  Y. Yamaguchi,et al.  EBI1/CCR7 is a new member of dendritic cell chemokine receptor that is up-regulated upon maturation. , 1998, Journal of immunology.

[8]  J. Mayordomo,et al.  Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity , 1996, The Journal of experimental medicine.

[9]  H. Oertel OBSERVATIONS CONCERNING LEUKÆEMIC LESIONS OF THE SKIN , 1899, The Journal of experimental medicine.

[10]  D. Morton,et al.  Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. , 1998, The Journal of investigative dermatology.

[11]  David J Mooney,et al.  Fabrication and in vitro testing of polymeric delivery system for condensed DNA. , 2003, Journal of biomedical materials research. Part A.

[12]  R. Steinman,et al.  Taking dendritic cells into medicine , 2007, Nature.

[13]  Robert Langer,et al.  Controlled Delivery Systems for Proteins Based on Poly(Lactic/Glycolic Acid) Microspheres , 1991, Pharmaceutical Research.

[14]  D J Mooney,et al.  Open pore biodegradable matrices formed with gas foaming. , 1998, Journal of biomedical materials research.

[15]  M. Kapsenberg Dendritic-cell control of pathogen-driven T-cell polarization , 2003, Nature Reviews Immunology.

[16]  C. Caux,et al.  Selective Recruitment of Immature and Mature Dendritic Cells by Distinct Chemokines Expressed in Different Anatomic Sites , 1998, The Journal of experimental medicine.

[17]  Dwaine F. Emerich,et al.  Cellular transplantation : from laboratory to clinic , 2007 .

[18]  S. Cingarlini,et al.  Therapeutic Effectiveness of Recombinant Cancer Vaccines Is Associated with a Prevalent T-Cell Receptor α Usage by Melanoma-specific CD8+ T Lymphocytes , 2004, Cancer Research.

[19]  G. Asherson,et al.  Distribution of immunogenic cells after painting with the contact sensitizers fluorescein isothiocyanate and oxazolone. Different sensitizers form immunogenic complexes with different cell populations. , 1980, Immunology.

[20]  D. Mooney,et al.  Polymeric system for dual growth factor delivery , 2001, Nature Biotechnology.

[21]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Franco Patrone,et al.  The use of dendritic cells in cancer immunotherapy. , 2008, Critical reviews in oncology/hematology.

[23]  R Bonecchi,et al.  Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. , 1998, Journal of immunology.

[24]  M. Merad,et al.  In Vivo Manipulation of Dendritic Cells Overcomes Tolerance to Unmodified Tumor-Associated Self Antigens and Induces Potent Antitumor Immunity1 , 2005, The Journal of Immunology.

[25]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[26]  Gwendalyn J Randolph,et al.  Migration of dendritic cell subsets and their precursors. , 2008, Annual review of immunology.

[27]  D. Klinman Immunotherapeutic uses of CpG oligodeoxynucleotides , 2004, Nature Reviews Immunology.

[28]  A. Grothey,et al.  Antiangiogenic therapy in cancer: a new era has begun. , 2005, Oncology.

[29]  S. Rosenberg,et al.  Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[30]  J. Richards,et al.  Sequential chemoimmunotherapy in the treatment of metastatic melanoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Rosenberg,et al.  Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells , 2003, The Journal of experimental medicine.

[32]  J. Saurat,et al.  Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis. , 2000, Cancer research.

[33]  M. Disis Clinical use of subcutaneous G-CSF or GM-CSF in malignancy. , 2005, Oncology.

[34]  Mary Fischer Implanon: a new contraceptive implant. , 2008, Journal of obstetric, gynecologic, and neonatal nursing : JOGNN.

[35]  R. Coffman,et al.  Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists , 2007, Nature Medicine.

[36]  I. Fidler Biological behavior of malignant melanoma cells correlated to their survival in vivo. , 1975, Cancer research.